JAK2 and essential thrombocythemia: Other studies identifying new candidate prognostic markers or potential therapeutic targets have described the possible role of MAPK14 in PV [70], EPB42, CALR, SLC4A1 and MPL [71], LCN2, JAK2, MMP8, CAMP, DEFA4, LTF, MPO, HBD, STAT4, EBF1 [72] in PMF, CDH6, EHD2, FUT1, KIF26A, LINC00346, PTPRN, SERF1A, SLC6A9 [73], and CALR in ET [74].